Financial Performance - The company's revenue for Q1 2025 was ¥176,466,917.68, a decrease of 4.37% compared to ¥184,532,679.41 in the same period last year[5] - Net profit attributable to shareholders was ¥7,431,617.71, down 67.32% from ¥22,737,202.98 year-on-year[5] - Basic and diluted earnings per share decreased by 76.32% to ¥0.09 from ¥0.38 in the same period last year[5] - The company's net profit for the current period is 7,431,617.71, a decrease of 67.24% compared to 22,737,202.98 in the previous period[24] - Operating profit for the current period is 7,410,767.37, down 71.73% from 26,187,330.39 in the previous period[24] - Total revenue from operating activities is 167,160,562.28, compared to 170,027,073.63 in the previous period, reflecting a decrease of 1.10%[27] Cash Flow - The net cash flow from operating activities was -¥36,061,657.52, representing a decline of 321.73% compared to -¥8,550,816.03 in the previous year[5] - The net cash flow from investment activities decreased by 72.01% to ¥22,709,137.00, mainly due to a reduction in the redemption of financial products[11] - The company experienced a 53.87% decrease in net cash flow from financing activities, attributed to increased cash payments for leases[11] - The net cash flow from operating activities is -36,061,657.52, worsening from -8,550,816.03 in the previous period[27] - The net cash flow from investment activities is 22,709,137.00, down from 81,122,056.14 in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,416,710,312.18, a decrease of 0.90% from ¥1,429,620,491.24 at the end of the previous year[5] - Total liabilities decreased from CNY 256.48 million to CNY 236.14 million during the same period[22] - Cash and cash equivalents at the end of the period amount to 473,169,430.70, down from 564,307,218.74 in the previous period[28] Shareholder Information - The largest shareholder, Shihezi Xitai Equity Investment Partnership, holds 18.58% of shares, totaling 14,773,473 shares[14] - The second-largest shareholder, Shihezi Ruixin Equity Investment Partnership, owns 8.05% of shares, amounting to 6,397,560 shares[14] - The total number of shares held by the top 10 shareholders is significant, with the largest three shareholders collectively holding over 34% of the company[14] - The company has a total of 31,995,562 restricted shares at the beginning of the period, with 5,460 shares released and 40,875 shares added, resulting in 32,030,977 restricted shares at the end of the period[16] - The release of restricted shares is scheduled for May 17, 2025, for several major shareholders[16] - The top 10 unrestricted shareholders include Shanghai Guanyu Investment Development Co., holding 5,474,040 shares, and other notable investors[14] - The total number of shares held by the top 10 unrestricted shareholders is 9,000,000 shares, indicating a concentrated ownership structure[14] Operational Highlights - The company faced pressure on gross margin and net margin due to intensified industry competition and a decline in new contract amounts in 2024[18] - As of the end of the reporting period, the total number of employees was 4,277, with over 4,050 being professional staff, serving more than 960 clinical trial institutions[18] - The company has undertaken over 3,800 international and domestic SMO projects, with 2,250 projects currently in execution[18] Research and Development - The company incurred research and development expenses of 9,059,623.94, an increase of 4.56% from 8,664,189.05 in the previous period[24] Future Plans - The actual controller plans to increase shareholding by CNY 6 million to CNY 9 million within six months from the announcement date[19] - The company completed the repurchase and cancellation of 5,460 restricted shares, reducing the total share capital from 79,508,000 shares to 79,502,540 shares[19]
普蕊斯(301257) - 2025 Q1 - 季度财报